Drug Trial Radar · NCT00142545
Long Term Safety and Efficacy of SC Apomorphine in Treatment of "Off" Episodes in Late-Stage Parkinson's Disease
Last checked: Nov 19, 2026Latest source record: Sep 2, 2005 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
800
Actual
Start
Jul 1999
Primary completion
Not stated
Study completion Jul 2005
Sponsor
- Lead sponsor
- Mylan Bertek PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Sep 2, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The current protocol is designed to satisfy the need for a compassionate use treatment protocol as well as for a long-term open label follow-up study.
Conditions
- Parkinson Disease
Interventions
apomorphine HCl injectionDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- adverse events (AE)s
- clinical laboratory tests
- vital signs
- electrocardiogram
- orthostatic monitoring
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Mylan Pharmaceuticals
Morgantown, West Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.